immatics biotechnologies GmbH (F:4A3) — Market Cap & Net Worth
Market Cap & Net Worth: immatics biotechnologies GmbH (4A3)
immatics biotechnologies GmbH (F:4A3) has a market capitalization of $1.20 Billion (€1.02 Billion) as of August 4, 2026. Listed on the F stock exchange, this Germany-based company holds position #8033 globally and #1085 in its home market, demonstrating a -7.62% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying immatics biotechnologies GmbH's stock price €7.64 by its total outstanding shares 134096576 (134.10 Million). See 4A3 capital expenditure intensity to understand how much of operating cash flow is reinvested back into capital assets.
immatics biotechnologies GmbH Market Cap History: 2020 to 2026
immatics biotechnologies GmbH's market capitalization history from 2020 to 2026. Data shows change from $1.29 Billion to $1.20 Billion (-5.55% CAGR).
immatics biotechnologies GmbH Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how immatics biotechnologies GmbH's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
27.63x
immatics biotechnologies GmbH's market cap is 27.63 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2020 | $1.29 Billion | $31.25 Million | -$229.06 Million | 41.33x | N/A |
| 2021 | $1.72 Billion | $34.76 Million | -$93.33 Million | 49.43x | N/A |
| 2022 | $1.26 Billion | $172.83 Million | $37.51 Million | 7.28x | 33.54x |
| 2023 | $1.51 Billion | $54.00 Million | -$94.65 Million | 28.02x | N/A |
| 2024 | $1.08 Billion | $155.84 Million | $15.22 Million | 6.94x | 71.08x |
| 2025 | $1.33 Billion | $48.27 Million | -$196.45 Million | 27.63x | N/A |
Competitor Companies of 4A3 by Market Capitalization
Companies near immatics biotechnologies GmbH in the global market cap rankings as of August 4, 2026.
Key companies related to immatics biotechnologies GmbH by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #222 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #423 globally with a market cap of $64.60 Billion USD.
- Argen-X (BR:ARGX): Ranked #541 globally with a market cap of $49.55 Billion USD ( €42.38 Billion EUR).
- UCB SA (BR:UCB): Ranked #564 globally with a market cap of $47.34 Billion USD ( €40.49 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #222 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $470.72 |
| #423 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $64.60 Billion | $759.24 |
| #541 | Argen-X | BR:ARGX | $49.55 Billion | €722.20 |
| #564 | UCB SA | BR:UCB | $47.34 Billion | €221.40 |
immatics biotechnologies GmbH Historical Marketcap From 2020 to 2026
Between 2020 and today, immatics biotechnologies GmbH's market cap moved from $1.29 Billion to $ 1.20 Billion, with a yearly change of -5.55%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €1.20 Billion | -10.23% |
| 2025 | €1.33 Billion | +23.26% |
| 2024 | €1.08 Billion | -28.50% |
| 2023 | €1.51 Billion | +20.23% |
| 2022 | €1.26 Billion | -26.77% |
| 2021 | €1.72 Billion | +33.01% |
| 2020 | €1.29 Billion | -- |
End of Day Market Cap According to Different Sources
On Aug 4th, 2026 the market cap of immatics biotechnologies GmbH was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.20 Billion USD |
| MoneyControl | $1.20 Billion USD |
| MarketWatch | $1.20 Billion USD |
| marketcap.company | $1.20 Billion USD |
| Reuters | $1.20 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About immatics biotechnologies GmbH
Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as adoptive cell therapies (ACT) and antibody-like TCR Bispecific… Read more